Nuvama initiated coverage on aerospace player Aequs with a 'Buy' rating and a target price of Rs 444, implying a 91% upside from the stock's previous closing price of Rs 232.
Aequs deserves a valuation premium above pharma CDMOs, as unlike molecules, aircraft programmes never expire, Nuvama said in its latest report, calling the company a sector outperformer. The shares of the company surged 4% on Tuesday morning.